Latest news with #AdaptiveBiotechnologiesCorporation
Yahoo
28-05-2025
- Business
- Yahoo
Adaptive Biotechnologies to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference
SEATTLE, May 28, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will be participating in the upcoming Goldman Sachs 46th Annual Global Healthcare Conference in Miami, FL. Adaptive Biotechnologies' management is scheduled to participate in a fireside chat on Wednesday, June 11th at 5:40 a.m. Pacific Time / 8:40 a.m. Eastern Time. Interested parties may access a live and archived webcast of the presentation on the 'Investors' section of the company website at: About Adaptive Biotechnologies Adaptive Biotechnologies ('we' or 'our') is a commercial-stage biotechnology company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. We believe the adaptive immune system is nature's most finely tuned diagnostic and therapeutic for most diseases, but the inability to decode it has prevented the medical community from fully leveraging its capabilities. Our proprietary immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed. We apply our platform to partner with biopharmaceutical companies, inform drug development, and develop clinical diagnostics across our two business segments: Minimal Residual Disease (MRD) and Immune Medicine. Our commercial products and clinical pipeline enable the diagnosis, monitoring, and treatment of diseases such as cancer and autoimmune disorders. Our goal is to develop and commercialize immune-driven clinical products tailored to each individual patient. ADAPTIVE INVESTORSKarina Calzadilla, Vice President, Investor Relations and FP&A201-396-1687investors@ ADAPTIVE MEDIAErica Jones, Associate Corporate Communications Director206-279-2423media@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
04-05-2025
- Business
- Yahoo
Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Released Earnings Last Week And Analysts Lifted Their Price Target To US$10.57
A week ago, Adaptive Biotechnologies Corporation (NASDAQ:ADPT) came out with a strong set of first-quarter numbers that could potentially lead to a re-rate of the stock. Revenue crushed expectations at US$52m, beating expectations by 24%. Adaptive Biotechnologies reported a statutory loss of US$0.20 per share, which - although not amazing - was much smaller than the analysts predicted. The analysts typically update their forecasts at each earnings report, and we can judge from their estimates whether their view of the company has changed or if there are any new concerns to be aware of. We've gathered the most recent statutory forecasts to see whether the analysts have changed their earnings models, following these results. Our free stock report includes 3 warning signs investors should be aware of before investing in Adaptive Biotechnologies. Read for free now. Taking into account the latest results, the consensus forecast from Adaptive Biotechnologies' eight analysts is for revenues of US$216.0m in 2025. This reflects a meaningful 14% improvement in revenue compared to the last 12 months. Losses are expected to be contained, narrowing 11% from last year to US$0.83. Yet prior to the latest earnings, the analysts had been forecasting revenues of US$212.7m and losses of US$0.92 per share in 2025. Although the revenue estimates have not really changed Adaptive Biotechnologies'future looks a little different to the past, with a favorable reduction in the loss per share forecasts in particular. View our latest analysis for Adaptive Biotechnologies The average price target rose 8.8% to US$10.57, with the analysts signalling that the forecast reduction in losses would be a positive for the stock's valuation. There's another way to think about price targets though, and that's to look at the range of price targets put forward by analysts, because a wide range of estimates could suggest a diverse view on possible outcomes for the business. There are some variant perceptions on Adaptive Biotechnologies, with the most bullish analyst valuing it at US$13.00 and the most bearish at US$7.00 per share. These price targets show that analysts do have some differing views on the business, but the estimates do not vary enough to suggest to us that some are betting on wild success or utter failure. One way to get more context on these forecasts is to look at how they compare to both past performance, and how other companies in the same industry are performing. The analysts are definitely expecting Adaptive Biotechnologies' growth to accelerate, with the forecast 19% annualised growth to the end of 2025 ranking favourably alongside historical growth of 13% per annum over the past five years. By contrast, our data suggests that other companies (with analyst coverage) in a similar industry are forecast to grow their revenue at 6.0% per year. Factoring in the forecast acceleration in revenue, it's pretty clear that Adaptive Biotechnologies is expected to grow much faster than its industry. The most important thing to take away is that the analysts reconfirmed their loss per share estimates for next year. Happily, there were no major changes to revenue forecasts, with the business still expected to grow faster than the wider industry. There was also a nice increase in the price target, with the analysts clearly feeling that the intrinsic value of the business is improving. With that said, the long-term trajectory of the company's earnings is a lot more important than next year. At Simply Wall St, we have a full range of analyst estimates for Adaptive Biotechnologies going out to 2027, and you can see them free on our platform here.. Even so, be aware that Adaptive Biotechnologies is showing 3 warning signs in our investment analysis , you should know about... Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Sign in to access your portfolio
Yahoo
05-02-2025
- Business
- Yahoo
Adaptive Biotechnologies to Participate in Upcoming Investor Conferences
SEATTLE, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation ('Adaptive Biotechnologies') (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will be participating in the following investor conferences. BTIG 12th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference in Snowbird, UTParticipating on Wednesday, February 12, 2025 TD Cowen 45th Annual Health Care Conference in Boston, MAFireside chat on Monday, March 3, 2025, at 11:10 a.m. Eastern Time Interested parties may access live and archived webcasts of the session on the 'Investors' section of the company website at: About Adaptive Biotechnologies Adaptive Biotechnologies ('we' or 'our') is a commercial-stage biotechnology company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. We believe the adaptive immune system is nature's most finely tuned diagnostic and therapeutic for most diseases, but the inability to decode it has prevented the medical community from fully leveraging its capabilities. Our proprietary immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed. We apply our platform to partner with biopharmaceutical companies, inform drug development, and develop clinical diagnostics across our two business areas: Minimal Residual Disease (MRD) and Immune Medicine. Our commercial products and clinical pipeline enable the diagnosis, monitoring, and treatment of diseases such as cancer, autoimmune disorders, and infectious diseases. Our goal is to develop and commercialize immune-driven clinical products tailored to each individual patient. ADAPTIVE INVESTORSKarina Calzadilla, Vice President, Investor Relations and FP&A201-396-1687investors@ ADAPTIVE MEDIAErica Jones, Associate Corporate Communications Director206-279-2423media@
